The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Safety Evaluation of Lipid Nanoparticle–Formulated Modified mRNA in the Sprague-Dawley Rat and Cynomolgus Monkey
Abstract
The pharmacology, pharmacokinetics, and safety of modified mRNA formulated in lipid nanoparticles (LNPs) were evaluated after repeat intravenous infusion to rats and monkeys. In both species, modified mRNA encoding the protein for human erythropoietin (hEPO) had predictable and consistent pharmacologic and toxicologic effects. Pharmacokinetic analysis conducted following the first dose showed that measured hEPO levels were maximal at 6 hours after the end of intravenous infusion and in excess of 100-fold the anticipated efficacious exposure (17.6 ng/ml) at the highest dose tested. 24 hEPO was pharmacologically active in both the rat and the monkey, as indicated by a significant increase in red blood cell mass parameters. The primary safety-related findings were caused by the exaggerated pharmacology of hEPO and included increased hematopoiesis in the liver, spleen, and bone marrow (rats) and minimal hemorrhage in the heart (monkeys). Additional primary safety-related findings in the rat included mildly increased white blood cell counts, changes in the coagulation parameters at all doses, as well as liver injury and release of interferon γ–inducible protein 10 in high-dose groups only. In the monkey, as seen with the parenteral administration of cationic LNPs, splenic necrosis and lymphocyte depletion were observed, accompanied with mild and reversible complement activation. These findings defined a well-tolerated dose level above the anticipated efficacious dose. Overall, these combined studies indicate that LNP-formulated modified mRNA can be administered by intravenous infusion in 2 toxicologically relevant test species and generate supratherapeutic levels of protein (hEPO) in vivo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In vivo application of lipid nanoparticles has been reported to induce liver and lung injuries in rodents170,173, which may be attributed to the cytotoxicity of the materials and the induction of”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [173]
In the citing paper
“Although the immunogenicity of these lipids has not yet been fully understood, complement system and Toll-like receptors may participate in innate immune activation170,173–175.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [173]
In the citing paper
“Cationic and ionizable lipids have also been reported to stimulate the secretion of pro-inflammatory cytokines and reactive oxygen species170–173.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [173]
Citations
Cites
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
mRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
Protein Therapeutics: A Summary and Pharmacological Classification
Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 2,161
Rational design of cationic lipids for siRNA delivery
Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1602 · Cited by 1,822 · cited 1×
“However, the application of lipid-based nanoparticle delivery systems, initially developed for the in vivo delivery of siRNA, has enabled systemic administration of modified mRNA.(22)”
BackgroundGilleron, J., Querbes, W., Zeigerer, A., Borodovsky, A., Marsico, G., Schubert, U., Manygoats, K., Seifert, S., Andree, C., Stöter, M., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2612 · Cited by 1,681
RNAi-mediated gene silencing in non-human primates
Zimmermann, T. S., Lee, A. C. H., Akinc, A., Bramlage, B., Bumcrot, D., Fedoruk, M. N., Harborth, J., Heyes, J. A., Jeffs, L. B., John, M., et al. (2006) · Nature · doi:10.1038/nature04688 · Cited by 1,357 · cited 1×
“The mRNA-loaded LNPs were generated via stepwise ethanol dilution, with an approach adapted from previously demonstrated methods.(13,30) The LNP formulation was prepared by dissolving the lipids (6Z,9Z,28Z,31Z)-heptatriaconta6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate (MC3), 2 Veterinary Pathology XX(X)”
MethodShatkin, A. J. (1976) · Cell · doi:10.1016/0092-8674(76)90128-8 · Cited by 1,180
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
Safety and efficacy of RNAi therapy for transthyretin amyloidosis
Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208760 · Cited by 971
Expression of therapeutic proteins after delivery of chemically modified mRNA in mice
Kormann, M. S. D., Hasenpusch, G., Aneja, M. K., Nica, G., Flemmer, A. W., Herber-Jonat, S., Huppmann, M., Mays, L. E., Illenyi, M., Schams, A., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1733 · Cited by 733
Research works printed but not linked: 1
- Casadevall N, 2003, Nephrol Dial Transplant, 18, viii37
Cited by
Sorted by citations
Items 101–194 of 194
Vaccine-induced immune thrombotic thrombocytopenia: what do we know hitherto?
Roytenberg, R., García‐Sastre, A., & Li, W. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1155727 · Cited by 21
“LNPs consist of phospholipids, cholesterol, PEGylated lipids, and ionizable lipids, which act in tandem to stabilize the LNP, prolong its circulation, and effectively deliver the housed mRNA to target cells (e.g., myocytes and antigen presenting cells) (45, 46).”
BackgroundInfluentialmRNA Vaccine Platform: mRNA Production and Delivery
Litvinova, V. R., Рудометов, А. П., Карпенко, Л. И., & Ilyichev, A. A. (2023) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162023020152 · Cited by 26
Ahn, J.-H., Lee, J., Roh, G., Lee, N.-Y., Bae, H.-J., Kwon, E., Han, K. M., Kim, J.-E., Park, H., Yoo, S., et al. (2024) · Archives of Toxicology · doi:10.1007/s00204-024-03912-1 · Cited by 24
“Several studies have conducted toxicological tests for mRNA vaccines in animal experimental models, adopting a protocol of repeated administration at set intervals (Dona-hue et al. 2023; Sedic et al. 2018; Stokes et al. 2020).”
Current knowledge on the tissue distribution of mRNA nanocarriers for therapeutic protein expression
Zadory, M., Lopez, E., Babity, S., Gravel, S., & Brambilla, D. (2022) · Biomaterials Science · doi:10.1039/d2bm00859a · Cited by 18
Wang, F., Zhang, M., Tian, M., Lou, J., Pan, L., Gao, X., Zhang, L., Lou, X., Zhu, L., Sheng, Y., et al. (2023) · Nano Research · doi:10.1007/s12274-023-6111-2 · Cited by 16
A brief review of mRNA therapeutics and delivery for bone tissue engineering
Rajendran, A. K., Amirthalingam, S., & Hwang, N. S.-Y. (2022) · RSC Advances · doi:10.1039/d2ra00713d · Cited by 16
Delivery of Circular mRNA via Degradable Lipid Nanoparticles against SARS-CoV-2 Delta VariantPreprint
Huang, K., Li, N., Li, Y., Zhu, J., Fan, Q., Yang, J., Gao, Y., Liu, Y., Hou, Q., Gao, S., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.12.491597 · Cited by 16
Advances of Nanotechnology Toward Vaccine Development Against Animal Infectious Diseases
Wang, X., Gao, X., Wang, L., Lin, J., & Liu, Y. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202305061 · Cited by 16
Recent Advances in Messenger Ribonucleic Acid (mRNA) Vaccines and Their Delivery Systems: A Review
Belay, W. Y., Nibret, G., & Aschale, Y. (2023) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s418314 · Cited by 16
Broudic, K., Laurent, S., Perkov, V., Simon, C., Garinot, M., Truchot, N., Latour, J., & Désert, P. (2023) · Journal of Applied Toxicology · doi:10.1002/jat.4548 · Cited by 15
“…in the same LNP vehicle (Broudic et al., 2022), based on the assumption that the safety profile of LNP/mRNA-based vaccines is mainly driven by the LNP component rather than by the mRNA (Hassett et al., 2019; Lutz et al., 2017; Marlowe et al., 2017; Sabnis et al., 2018; Sedic et al., 2018).”
BackgroundmRNA biotherapeutics landscape for rare genetic disorders
Iyer, V. R., Praveen Reddy., P., Kaduskar, B., Moharir, S. C., & Mishra, R. K. (2024) · Journal of Biosciences · doi:10.1007/s12038-023-00415-6 · Cited by 17
“D-Lin-MC3-DMA was further tested for mRNA technology and found to be exhibit mild toxicity in rats and monkeys (Sedic et al .”
Lipid Nanoparticle-Mediated Delivery of miRNA Mimics to Myeloid Cells
Kang, E. Y., & Kortylewski, M. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3331-1_24 · Cited by 15
Wang, S., Guo, B., Wang, H., & Yang, F. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105547 · Cited by 14
RNA encoded peptide barcodes enable efficient in vivo screening of RNA delivery systems
Odunze, U., Rustogi, N., Devine, P., Miller, L., Pereira, S. G. T., Vashist, S., Snijder, H. J., Corkill, D. J., Sabirsh, A., Douthwaite, J. A., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae648 · Cited by 16
“The relationship between the dose of hEPO mRNA and the amount of protein expressed in vivo has been shown to not be linear ( 21 ) and the relative hEPO production from different LNPs could be different at different doses ( 5 ).”
BackgroundGenome Editing Therapy for the Blood: Ex Vivo Success and In Vivo Prospects
George, C. A., Sahu, S. U., de Oñate, L., Souza, B. S. D. F., & Wilson, R. C. (2024) · The CRISPR Journal · doi:10.1089/crispr.2024.0036 · Cited by 15
“73 It has been shown that the rate of protein synthesis in HSCs is lower than in other stem cells, which suggests the necessity of greater doses of mRNA — and thus LNP — to meet editing thresholds.”
Yu, M., Liu, D., Shah, P., Qiu, B., Mathew, A., Yao, L., Guan, T., Cong, H., & Zhang, N. (2025) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.4c02373 · Cited by 13
Nonclinical Testing Evaluation of Liposomes as Drug Delivery Systems
Baldrick, P. (2022) · International Journal of Toxicology · doi:10.1177/10915818221148436 · Cited by 12
“An example is with modified mRNA encoding protein for human erythropoietin in a LNP composed of lipids (6Z,9Z,28Z,31Z)-heptatriaconta6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate (MC3), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), cholesterol and 1,2-dimyristoyl-rac-glycerol, methoxypolyethylene glycol (PEG…”
BackgroundMethodInfluentialLuozhong, S., Li, R., Tian, Z., Cao, Z., Bhashyam, D., Zhang, P., McIlhenny, K., Fang, L., McMullen, P., & Jiang, S. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c07903 · Cited by 12
Measurement of mRNA Therapeutics: Method Development and Validation Challenges
Henderson, N., & Wilson, A. (2019) · Bioanalysis · doi:10.4155/bio-2019-0120 · Cited by 12
Du, X., Nakanishi, H., Yamada, T., Sin, Y., Minegishi, K., Motohashi, N., Aoki, Y., & Itaka, K. (2025) · Advanced Science · doi:10.1002/advs.202409065 · Cited by 11
In Vivo CAR-T Therapies—A New Era of Programmable Immunity
Pierini, S., Qureshi, R., Pustylnikov, S., Bartosh, Z., & Akimova, T. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27041737 · Cited by 13
“To assess safety and tolerability, LNP-sensitive species like Sprague-Dawley rats and cynomolgus monkeys [111] were treated with CD5-L829-tLNP.”
Shaharyar, M. A., Bhowmik, R., Al-Abbasi, F. A., AlGhamdi, S. A., Alghamdi, A. M., Sarkar, A., Kazmi, I. A., & Karmakar, S. (2023) · Vaccines · doi:10.3390/vaccines11020241 · Cited by 12
“For instance, mRNA was transported to the liver in mice using LNPs in conjugation withcKK-E12 [121,122], C12-200 [123], and DLin-MC3-DMA [124].”
McCarthy, S., Rohde, C. B., Angel, M., Masterson, C. H., MacLoughlin, R. J., Fandiño, J., González, H. E., Byrnes, D., Laffey, J. G., & O’Toole, D. P. (2023) · Nucleic Acid Therapeutics · doi:10.1089/nat.2022.0049 · Cited by 11
Li, L., Luo, M., Zhou, L., Wang, Y., Jiao, Y., Wang, C., Gong, C., Cen, X., & Yao, S. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125282 · Cited by 11
Applications and challenges of biomaterial mediated mRNA delivery
Fang, H., & Chen, Q. (2022) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2022.00093 · Cited by 12
“00093 Page 431 Additionally, other scientists also used DLin-MC3-DMA to mediate mRNA for expressing therapeutic proteins including human erythropoietin and frataxin in vivo [46, 47].”
Xu, X., Cui, L., Zhang, Y., & Gu, J. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.11.023 · Cited by 13
“…hybridization and branched DNA-mediated signal amplification (rather than target amplification) to generate a chemiluminescent signal directly proportional to the original nucleic acid amount, providing a highly sensitive method for quantifying low-abundance targets such as in vivo mRNA 60,62,141 .”
Raines, S. L. M., Falcinelli, S. D., Peterson, J. J., Gulck, E. R. V., Allard, B., Kirchherr, J., Vega, J. B., Nájera, I., Boden, D., Archin, N. M., et al. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00201-24 · Cited by 10
du Preez, H. N., Lin, J., Maguire, G. E. M., Aldous, C. M., & Kruger, H. G. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14296 · Cited by 12
“62 In vitro, it has been shown that cationic LNPs, whether or not they are complexed with nucleic acids, are highly toxic to macrophages.”
Choi, A. S., Moon, T. J., Bhalotia, A., Rajan, A., Ogunnaike, L., Hutchinson, D. W., Hwang, I., Gokhale, A., Kim, J. N., Ma, T., et al. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c01039 · Cited by 11
Nayak, N., Basha, S. A., Tripathi, S. K., et al. (2021) · Materials Chemistry and Physics · doi:10.1016/j.matchemphys.2021.125187 · Cited by 10
Empowering gene delivery with protein engineering platforms
Kizerwetter, M., Pietz, K., Tomasovic, L. M., & Spangler, J. B. (2022) · Gene Therapy · doi:10.1038/s41434-022-00379-6 · Cited by 10
Alishetty, S., Carrasco, M. J., Alameh, M., Paige, M. A., Said, H., Wright, L., Narayanan, A., Alem, F., Hernandez, K. R., Gillevet, P. M., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-798453/v1 · Cited by 10
Yang, H., Li, J., Song, C., Li, H., Luo, Q., & Chen, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041743 · Cited by 11
“LNPs can activate serum complement, causing non-IgE-mediated hypersensitivity reactions known as complement activation-related pseudoallergy, which may result in anaphylactic shock [85–87].”
Synthesis and bioactivity of a novel surfactin-based lipopeptide for mRNA delivery
Alqahtani, M. S., Syed, R., Alqahtani, A. S., Almarfadi, O. M., Roni, M. A., & Sadhu, S. S. (2024) · Nanoscale Advances · doi:10.1039/d4na00404c · Cited by 8
Significance of VLPs in Vlp-circRNA vaccines: a vaccine candidate or delivery vehicle?
Gupta, R., Arora, K., Arora, N. M., & Kundu, P. K. (2024) · RNA Biology · doi:10.1080/15476286.2024.2399307 · Cited by 11
Evaluation of non-clinical toxicity studies of COVID-19 vaccines
Schilder, N., Tiesjema, B., Theunissen, P. T., et al. (2023) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2023.105438 · Cited by 8
Adapting ADME and Pharmacokinetic Analysis to the Next Generation of Therapeutic Modalities
Hochman, J. H. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.09.057 · Cited by 8
mRNA—From COVID-19 Treatment to Cancer Immunotherapy
Kŕause, W. (2023) · Biomedicines · doi:10.3390/biomedicines11020308 · Cited by 8
“In addition to LNP, other types of formulations such as liposomes [79], ionizable lipids [80], pH-dependent ionizable materials [81], MC3 [70], polymers [82], dendrimers [83], cell-penetrating peptides [84], and other materials have been investigated [44,56,85,86].”
Retinal organoid and gene editing for basic and translational research
Cheng, Y.-M., Ma, C., Jin, K., & Jin, Z. (2023) · Vision Research · doi:10.1016/j.visres.2023.108273 · Cited by 8
Clinical Toxicity of Nanomedicines
Ahamad, N., Bhardwaj, P., Bhatia, E., & Banerjee, R. (2020) · Springer eBooks · doi:10.1007/978-981-15-6255-6_20 · Cited by 8
Hsia, T., & Chen, Y. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114234 · Cited by 7
Immunology of biodegradable nanoparticles: a brief overview on a wide growing field
Pisani, A., & Bardi, G. (2021) · Exploration of Immunology · doi:10.37349/ei.2021.00006 · Cited by 7
“As for the other described biodegradable NPs, immunotoxicity, pro-inflammatory cytokines production, CARPA and eventually, anaphylactic shock are mainly ruled by the surface chemistry determining their PC and tissue-specific molecule adhesion [90, 91].”
BackgroundmRNA as a Therapeutics: Understanding mRNA Vaccines
Oğuz, F., & Atmaca, H. (2021) · Advanced Pharmaceutical Bulletin · doi:10.34172/apb.2022.028 · Cited by 8
“This is a promising step to develop a protective vaccine against the Ebola virus.(55,56)”
BackgroundHawthorne, G., Henderson, N., Hölttä, M., et al. (2019) · Bioanalysis · doi:10.4155/bio-2019-0138 · Cited by 7
Martin, S., McConnell, R. E., Harrison, R. A., Jang, S. C., Sia, C. L., Kamerkar, S., Duboff, A. G., Jacob, L. M., Finn, J. D., & Estes, S. D. (2023) · Biotechnology and Bioengineering · doi:10.1002/bit.28401 · Cited by 6
“along with toxicity and adverse immunological reactions (Lokugamage et al., 2020; Sedic et al., 2018; Szebeni, 2014).”
BackgroundGuelman, S. A., Zhou, Y., Brady, A. C., & Peng, K. (2022) · The AAPS Journal · doi:10.1208/s12248-022-00709-x · Cited by 6
“The bDNA platform was also applied in a toxicokinetic study in which the mRNA encoding human erythropoietin could be measured in rat plasma after infusion of mRNAlipid nanoparticles (24).”
MethodPascolo, S. (2023) · European Journal of Immunology · doi:10.1002/eji.202249941 · Cited by 6
Lipid nanoparticle mediated mRNA delivery in cancer immunotherapy
Asthana, G. S., Bhattacharjee, S., Kumar, J., Sayyed, S., Jindal, A., Kumar, P., Chinchane, A., Bhattacharyya, A., Jaiswal, R., Kulkarni, S., et al. (2025) · Advances in immunology · doi:10.1016/bs.ai.2025.02.001 · Cited by 5
Oligonucleotide therapeutics in sports? An antidoping perspective
Parr, M. K., & Keiler, A. M. (2024) · Archiv der Pharmazie · doi:10.1002/ardp.202400404 · Cited by 5
Saha, S., Tandon, R., Sanku, J., Kumari, A., Shukla, R., & Srivastava, N. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125463 · Cited by 6
Lipid-based nanoparticles and their recent advances
Sujeevan, O. (2024) · GSC Advanced Research and Reviews · doi:10.30574/gscarr.2024.18.3.0096 · Cited by 5
“Nanoparticles often get trapped in endosomes and degraded in lysosomes after cellular uptake, resulting in a loss of encapsulated biomolecules before their therapeutic effects can be exerted [47].”
BackgroundDelivery Aspects for Implementing siRNA Therapeutics for Blood Diseases
Dezfouli, S. A., Michailides, M. E., & Uludağ, H. (2024) · Biochemistry · doi:10.1021/acs.biochem.4c00327 · Cited by 5
Sarode, A., Ortiz, C., Derstepanian, T., Vargas‐Montoya, N., Patel, P., Khadse, N., Manna, S., Landis, R. F., Skaleski, J., Boeglin, L., et al. (2025) · Advanced Materials · doi:10.1002/adma.202517893 · Cited by 4
Chen, Y., Liu, Q., Wang, C., Chen, S., Li, S., Liu, J., Luo, L., Zhang, Z., Cai, J., Huang, M., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.128136 · Cited by 5
Toxicologic Pathology Forum: mRNA Vaccine Safety–Separating Fact From Fiction
Sellers, R. S., & Dormitzer, P. R. (2024) · Toxicologic Pathology · doi:10.1177/01926233241278298 · Cited by 4
“81 However, some high-profile publications have inaccurately reported nonclinical safety study data from mRNA-LNP COVID-19 vaccines.”
BackgroundOngun, M., Lokras, A. G., Foged, C., & Thakur, A. (2022) · RNA technologies · doi:10.1007/978-3-031-08415-7_11 · Cited by 4
Healthspan Extension through Innovative Genetic Medicines
Garcia, H., Brown, D. W., Scholz, M., & Lewis, J. D. (2021) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0000000000009674 · Cited by 6
Novel Swelling‐Lytic Cell Death Triggered by Cargo‐Free Ionizable Lipid Nanoparticles
Wu, J., Zhao, Z., Wu, H., Lin, S., Huang, L., Chen, G., Yang, Y., Wang, H., Yan, H., Yonghui, S., et al. (2025) · Advanced Science · doi:10.1002/advs.202509208 · Cited by 4
Hua, Z., Shen, Y., & Zhou, X. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18030282 · Cited by 5
“In addition, LNPs may also induce serum complement activation, leading to a non-IgE mediated hypersensitivity reaction known as complement activation-related pseudoallergy (CARPA), which can ultimately result in anaphylaxis [48,49].”
Qiao, P., Yu, J., Li, C., Chen, B., & Wang, Y. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114820 · Cited by 3
Pather, S., Charpentier, N., van den Ouweland, F., Rizzi, R., Finlayson, A., Salisch, N. C., Muik, A., Lindemann, C., Khanim, R., Abdul-Jawad, S., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.126165 · Cited by 3
Buckley, L. A., Sutherland, J. E., Borude, P. C., Broudic, K., Collin, P., Hillegas, A., MacLauchlin, C., Saleh, A. F. A., Sharma, A. M., Thomas, J. M., et al. (2025) · International Journal of Toxicology · doi:10.1177/10915818251320631 · Cited by 6
“40,54,55 However, results of complement assays from animal models do not always predict clinical reactions.”
Dog-specific hemorrhagic changes induced by liposomal formulations, in the liver and the gallbladder
Makita-Suzuki, K., Kakinuma, C., Inomata, A., Shimada, Y., Hara, T., & Yao, T. (2019) · Journal of Toxicologic Pathology · doi:10.1293/tox.2019-0029 · Cited by 3
Hardianto, A., Janitra, R. S., Widayat, W., Yusuf, M., Nurainy, N., & Subroto, T. (2025) · Scientific Reports · doi:10.1038/s41598-025-20340-y · Cited by 3
“The ratio of SM-102:Cholesterol: DSPC: DMG-PEG2000 used was 50:38.5:10:1.5, which was found to be effective based on literature 6,15,16 .”
InfluentialBathula, N. V., Casmil, I. C., Friesen, J. J., Yuan, E., Liao, S., Maiti, B., Liou, J., Lai, M.-J., Li, S., Chen, S., et al. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114736 · Cited by 3
Feng, Y., Zhao, Y., Han, J., Li, F., Li, G., Wang, B., Chen, Q., & Song, J. (2026) · Nano Research · doi:10.26599/nr.2026.94908571 · Cited by 3
Shi, P., Liu, H., Refaat, A., Nguyen, T., Nguyen, A., Miao, K., Song, Y., Trépout, S., Tabor, R. F., de Campo, L., et al. (2026) · Small · doi:10.1002/smll.202511946 · Cited by 2
Clinical trials, future prospects and challenges of drug delivery in combating metabolic disorders
Zakir, F., Mohapatra, S., Aftab, B., et al. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99616-7.00018-9 · Cited by 2
Chen, C., Kooi, A. V., Cavedon, A., Cai, X., Hoggatt, J., Martini, P. G. V., & Miao, C. H. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.102043 · Cited by 3
Nanosupplements and Animal Health
Bertero, A., SPICER, L. J., Coccini, T., & Caloni, F. (2019) · Springer eBooks · doi:10.1007/978-3-030-04624-8_54 · Cited by 2
mRNA-Vaccine Platform: Features of Obtaining and Delivery of mRNA
Litvinova, V. R., Рудометов, А. П., Карпенко, Л. И., & Ilyichev, A. A. (2023) · Биоорганическая химия · doi:10.31857/s013234232302015x · Cited by 2
Advanced drug delivery systems for enhancing the efficacy of RNA-based therapeutics
Alhabib, N. A., Almaniea, M. A., Alehaidib, S. M., Almansour, M. A., Aldosary, M. S., Almegbel, M. T., Alsubaie, S. A., & Alzahrani, A. M. (2022) · International Journal of Health Sciences · doi:10.53730/ijhs.v6ns10.15029 · Cited by 1
Harnessing mRNA vaccines for viral diseases: bottleneck and breakthrough
Mishra, V. K., Ranjan, A., & Mishra, Y. (2025) · Exploration of Immunology · doi:10.37349/ei.2025.1003212 · Cited by 1
Lv, H., Liu, W., Zhang, M., Gao, X., Liu, F., & Yang, C. (2026) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2026.115810 · Cited by 1
Walters, A. A., Hanafy, B. I., Lu, C., Marelli, S., Zam, A., Liu, K., Foreman, R. E., Soundararajan, R., Collin, P., Lindfors, L., et al. (2026) · Small · doi:10.1002/smll.74283 · Cited by 3
“Importantly, given the established association between elevated IFN γ /IP-10 signatures, vaccine efficacy, and myocarditis risk [14, 16–20,”
M6A-regulated LncRNA7825 maintains epithelial barrier integrity to restrict bacterial infection
Xu, H., Wu, X., Shi, L., Jiang, M., Wang, C., Guo, A., & Hu, C. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.117167 · Cited by 1
Non-invasive nanoparticle barcoding in nonhuman primates
Jang, B., Zenhausern, R., Lian, L., Gentry, K., Abbas, A. M., Rudden, S., Shin, Y.-J., Doan, J., Loughrey, D., Curran, E. H., et al. (2026) · Nature Biotechnology · doi:10.1038/s41587-026-03262-6 · Cited by 1
Medical Use of mRNA-Based Directed Gene Delivery
Matin, A., & Forterre, A. V. (2022) · RNA technologies · doi:10.1007/978-3-031-08415-7_5 · Cited by 1
Lipid nanoparticles for delivery of gene editing components
Kang, D. D., & Dong, Y. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-822425-0.00096-8 · Cited by 1
A Peptide Barcode Based Approach for Efficient in vivo Screening of RNA Delivery SystemsPreprint
Odunze, U., Rustogi, N., Devine, P., Miller, L., Pereira, S., Vashist, S., Snijder, A., Corkill, D. J., Sabirsh, A., Douthwaite, J. A., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2386865/v1 · Cited by 1
Peptide nanoparticles for systemic mRNA delivery in rodents and non-human primatesPreprint
Lehto, T., Sork, H., Lorents, A., Rädler, J., Bazaz, S., Roudi, S., Gustafsson, O., Boukary, O., Talgre, I. R., Hällbrink, M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.26.690657 · Cited by 1
“Compared to LNPs, which often require extended infusion times and still induce strong immune activation [38–41], hPep3 PNPs appear less reactogenic and more practical for systemic administration.”
InfluentialPaganelli, C. C. D. M. A. C. D. G. (2006) · Filmcritica
Sellers, R. S., & Nelson, K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821047-5.00029-4
Systemic Senolysis in Naturally Aged Mice Using a FAST-PLV Gene Therapy ApproachPreprint
Lewis, J. D., Garcia, H., Brown, D., Raturi, A., Nehme, J., Bhandari, P., Wee, P., Malavolta, M., Grin, L., Vega, H., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-5575296/v1
Araya, S., Barle, E. L., Wiesner, L., Blum, K., Hashimoto, K., Fisher, C., Schwind, M., Galati, G., Sehner, C., Pfister, T., et al. (2025) · Journal of Occupational and Environmental Hygiene · doi:10.1080/15459624.2025.2485080
“For example, the permanently cationic lipid component of the lipoplexes often causes inflammatory changes (Filion and Phillips 1997; Lv et al. 2006; Ndeupen et al. 2021; Samaridou et al. 2020; Sedic et al. 2018; Tao et al. 2011).”
Murata, Y., Kitamura, S., Asaoka, Y., et al. (2026) · The Journal of Toxicological Sciences · doi:10.2131/jts.51.201
Intravenous administration of LNP-mRNA therapeutics
Dahiya, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45006-8.00011-2
mRNA-based melanoma vaccines targeting gp100 and TRP2 macromolecules
Kakroudi, M. H., Rezvanimehr, A., Zolfaghari, K., Baghaei-Shiva, G., Abbasi, H., Pourashory, M., Yazdanpanah, N., Saleki, K., & Rezaei, N. (2026) · Discover Oncology · doi:10.1007/s12672-026-04811-w · Cited by 1
“…(hEPO) mRNA in monkey and rat models. rats exhibited elevated liver enzymes, changes in coagulation parameters, and increased levels of IFN-γ–induced proteins, whereas monkeys showed splenic necrosis, lymphocyte depletion, and mild, reversible activation of the complement system [154].”
Chen, J., Zhang, X., Zhang, J. N., Ren, H., Xie, J., & Ma, R. (2026) · Current Medicinal Chemistry · doi:10.2174/0109298673413607251209115328
Draycheva, A., Millecam, J., & Caba, E. (2026) · International Journal of Toxicology · doi:10.1177/10915818261446630
Jugniot, N. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119213
A Bioorthogonal Desilylation System Potentiates mRNA Therapeutics in Tumors
Zhang, M., Wang, C., Xu, X., Ding, Z., Chen, J., Guo, Z., & Liu, Z. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.6c09548
Accelerated discovery of thermostable mRNA–lipid nanoparticle vaccines using data-efficient AI
Tian, J., Tran, K. T. M., Pogostin, B. H., Sheridan, O., Mursalova, S., Lee, A. H., Liu, S., Hamkins, J., Antov, D., Power, A. L., et al. (2026) · Nature Biotechnology · doi:10.1038/s41587-026-03331-w · Cited by 1
Metadata
- Authors
- Sedic, M., Senn, J. J., Lynn, A., Laska, M., Smith, M., Platz, S. J., Bolen, J., Hoge, S., Bulychev, A., Jacquinet, E., Bartlett, V., & Smith, P. F.
- Affiliations
- Moderna Therapeutics (United States) (US)
- AstraZeneca, Melbourn, Royston, UK
- PureTech (United States) (US)
- Akcea Therapeutics, Cambridge, MA
- Alnylam Pharmaceuticals (United States) (US)
- Corresponding author
- Senn, Joseph J.
- Venue
- Veterinary Pathology
- Publisher
- SAGE Publications
- Published
- 2017-11-30
- Volume
- 55
- Issue
- 2
- Pages
- 341-354
- ISSN
- 0300-9858 (ISSN-L)
- 1544-2217
- OpenAlex
- W2774359469
- Semantic Scholar
- ff6e62a333b9a5177911689bb2e6b1d42baa1047
- Cited by
- 195
- References
- 29
- Citations by year
- 2026: 19 · 2025: 22 · 2024: 29 · 2023: 36 · 2022: 36 · 2021: 23 · 2020: 13 · 2019: 10 · 2018: 6
- FWCI
- 3.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Veterinary Pathology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Moderna
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Keywords
- modified mRNA, human erythropoietin, intravenous infusion, hematopoiesis, splenic necrosis, lymphocyte depletion, complement activation, CXCL10, liver injury, coagulation parameters, nonclinical safety evaluation
- MeSH terms
- Animals, Blood Coagulation, Erythropoietin, Female, Hematopoiesis, Infusions, Intravenous, Leukocyte Count, Lipids, Macaca fascicularis, Male, RNA, Messenger, Rats, Sprague-Dawley, Rats, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
